Skip to main content
. Author manuscript; available in PMC: 2017 Feb 1.
Published in final edited form as: Int J Cancer. 2015 Aug 21;138(3):770–775. doi: 10.1002/ijc.29716

Figure 1. MK2−/− mice exposed to AOM/DSS do not develop neoplasms and have substantially decreased cytokine production compared to WT mice.

Figure 1

AOM/DSS treated mice develop A) multiple neoplasms, while MK2−/− mice do not. H&E staining indicates that B) AOM/DSS treated WT mice developed defined neoplasms with dysplastic proliferation of the colonic epithelium compared to C) architectural disarray of mucosal tissue consistent with chronic injury from multiple DSS treatments, while D) AOM/DSS treated MK2−/− mice displayed no visible signs of dysplasia or mucosal damage. AOM/DSS treated MK2−/− mice have significantly decreased E) IL-1α, F) IL-1β, G) IL-6, and H) TNF-α in organ culture supernatants compared to WT mice by multiplex bead array. N=7 for WT mice and 8 for MK2−/− mice in duplicate experiments.